Veru (VERU) Scheduled to Post Quarterly Earnings on Thursday

Veru (NASDAQ:VERU) is scheduled to be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $4.14 million for the quarter, compared to analyst estimates of $3.00 million. Veru had a negative return on equity of 130.13% and a negative net margin of 265.27%. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Veru Price Performance

Shares of NASDAQ:VERU opened at $0.86 on Friday. The business’s 50-day moving average is $0.92 and its 200-day moving average is $0.88. Veru has a 1 year low of $0.36 and a 1 year high of $1.92. The company has a market capitalization of $126.55 million, a price-to-earnings ratio of -2.65 and a beta of -0.44.

Insider Buying and Selling at Veru

In other Veru news, CEO Mitchell Shuster Steiner sold 28,066 shares of the stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $1.32, for a total value of $37,047.12. Following the completion of the sale, the chief executive officer now owns 7,012,892 shares in the company, valued at approximately $9,257,017.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders have sold 181,970 shares of company stock worth $250,075. Corporate insiders own 14.20% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on VERU shares. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Veru in a research report on Monday, May 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price target (down from $7.00) on shares of Veru in a research note on Monday, April 15th. Finally, B. Riley initiated coverage on Veru in a research note on Tuesday, May 14th. They issued a “buy” rating and a $5.00 target price for the company.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.